Latest Healthcare News

Monash IVF Group has announced the resignation of CEO Michael Knaap, with CFO Malik Jainudeen stepping in as Acting CEO during the leadership transition.

dorsaVi has secured exclusive worldwide rights to cutting-edge RRAM technology from NTU Singapore, promising to revolutionize its wearable sensor products with enhanced performance and energy efficiency. This strategic move positions the company for expansion into healthcare, elite sports, and industrial IoT markets.

Opyl Limited has secured strategic collaborations with two leading contract research organisations, integrating its AI-driven TrialKey platform into cardiovascular, oncology, and rare disease clinical trials to enhance trial design and accelerate commercial growth.

ASX Limited’s 2025 Investor Forum reveals steady progress on its five-year strategy, highlighting technology modernization, operational risk management, and a focus on data-driven growth. The exchange outlines capital expenditure plans and expense controls aimed at sustaining shareholder value amid evolving market demands.

Cleo Diagnostics unveils a pioneering blood test for early ovarian cancer detection, boasting superior accuracy to existing methods and targeting a significant U.S. market opportunity.

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

Olympus Corporation has launched a nationwide emphysema screening campaign in the US powered by 4DMedical’s AI lung density analysis, marking a major commercial milestone for the Australian medtech firm.

Radiopharm Theranostics has secured FDA Fast Track designation for RAD101, a novel imaging agent aimed at improving diagnosis of recurrent brain metastases. The move could speed development and regulatory review as the company advances its Phase 2 clinical trial.

Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.

Chimeric Therapeutics has secured a $2.5 million advance against its FY25 R&D tax incentive, bolstering funding for its clinical trial pipeline and operational needs. This move complements recent capital raises and underscores the company’s strategic financial management amid its oncology-focused cell therapy development.

Careteq Limited has raised $625,000 through a convertible note from investor Antanas Guoga and loans from its board, strengthening its working capital position for the medium term.

Monash IVF has disclosed a significant embryo transfer error at its Clayton laboratory, prompting an internal investigation and expanded independent review. The company is implementing new safeguards while maintaining its profit outlook.